Is Egrifta (Tesamorelin) Legal in Florida? How to Access It Legally

HealthRX.com

Egrifta is a prescription drug approved for one use

Print or save as PDF

Key numbers

  • 1.4 mgEgrifta SV label daily dose, injected subcutaneously into the abdomenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.28 mgEgrifta WR label daily dose, injected subcutaneously into the abdomenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 5%Share of trial patients with HbA1c 6.5% or higher by week 26 on tesamorelin, versus 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • FDA status / Approved prescription drug, BLA 022505, first approved November 10, 2010 [1]
  • Current labels / Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026 [2][3]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy only [2]
  • Doses / Egrifta SV 1.4 mg daily; Egrifta WR 1.28 mg daily, subcutaneous into the abdomen [2][3]
  • Compounding / No category-based FDA statement; on no category of the bulk-substance lists [4][5][6]
  • Sport / WADA names it in S2.2.4; prohibited at all times [7][8]

What is Egrifta's federal status?

Egrifta was approved by FDA on November 10, 2010 under application BLA 022505 as a new molecular entity, and its marketing status is prescription [1]. The current labels are Egrifta SV and Egrifta WR, both dated July 29, 2026 and both given once daily by subcutaneous injection [2][3]. Tesamorelin is a synthetic analog of human growth hormone-releasing factor, not growth hormone itself [2].

What is it approved to treat?

One use: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label states that long-term cardiovascular safety has not been established, asks prescribers to weigh the risk and benefit of continuing in patients who have not had a reduction in visceral adipose tissue, and says it is not indicated for weight loss management because its effect on weight is neutral [2].

The Egrifta SV label gives 1.4 mg (0.35 mL of the reconstituted solution) once daily, and the Egrifta WR label gives 1.28 mg (0.16 mL) once daily, both injected into the abdomen with site rotation; the labels state the two are not substitutable [2][3]. The 2 mg daily dose used in the trials was of the original 1 mg/vial product [2].

Questions worth asking

Choose the questions you want to keep

Can tesamorelin be compounded?

FDA has made no category-based statement about compounding tesamorelin. It does not appear on FDA's list of bulk substances that may present significant safety risks (content dated 04/22/2026) [4], and it appears in no category of FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or of FDA's list for outsourcing facilities (updated March 21, 2025) [5][6]. It is already a component of an FDA-approved drug, Egrifta [1]. It is not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [9][10].

FDA says compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they reach patients [11]. It also notes that compounding conditions include valid patient-specific prescriptions for some compounders, while outsourcing facilities may also supply drugs in response to a health care provider's order that is not for an identified patient [11].

Does anything else affect its legal status?

Separately from drug law, tesamorelin is prohibited in sport. WADA's Prohibited List names it in section S2.2.4 among growth hormone releasing factors, and S2 substances are prohibited at all times, in and out of competition [7]. It is on the 2026 List and stays on the 2027 List [7][8].

What does the label say to watch for?

Contraindications are disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2]. The label says to monitor IGF-1; among patients treated 26 weeks in the trials, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [2]. It also says to evaluate glucose before and during therapy. In the trials, HbA1c of 6.5% or higher by week 26 occurred in 5% on tesamorelin versus 1% on placebo (hazard ratio about 3.3, 95% CI 1.4 to 9.6) [2]. The label says patients receiving glucocorticoid replacement for hypoadrenalism may need higher maintenance or stress doses after starting, with cortisone acetate and prednisone affected more than other steroids [2].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. What does the article say the label asks patients to have monitored during treatment?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is Egrifta legal in Florida?
Egrifta is an FDA-approved prescription drug (application BLA 022505, first approved November 10, 2010) and is available by prescription [1]. This page covers the federal position and does not describe Florida-specific rules.
What is the approved dose of tesamorelin?
The Egrifta SV label gives 1.4 mg once daily and the Egrifta WR label gives 1.28 mg once daily, both subcutaneous into the abdomen; the labels say the two are not substitutable [2][3].
Can tesamorelin be compounded?
FDA has made no category-based statement about compounding it: tesamorelin is not on FDA's significant-safety-risk list and appears in no category of the bulk-substance lists for state-licensed pharmacies and physicians or for outsourcing facilities [4][5][6].
Is tesamorelin banned in sport?
Yes. WADA names it in section S2.2.4 and prohibits it at all times, in and out of competition [7][8].
Is tesamorelin approved for weight loss?
No. The label states it is not indicated for weight loss management because it has a weight-neutral effect [2].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Can you get tesamorelin legally?

Yes, tesamorelin is legal at the federal level. Egrifta is an FDA-approved prescription drug, first approved November 10, 2010 under application BLA 022505, and it is available by prescription. Florida-specific rules are not covered here.

Can I get a prescription for tesamorelin?

It is available by prescription, since Egrifta is an FDA-approved prescription drug. The information does not describe how to obtain a prescription or whether one can be arranged online. Its one labeled use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.

Show all 11 referencesHide references
Evidence overview for Is Egrifta (Tesamorelin) Legal in Florida? How to Access It Legally